NO20062398L - Daglig, oral, kontrollert frigivnings oksycodon-doserings form - Google Patents
Daglig, oral, kontrollert frigivnings oksycodon-doserings formInfo
- Publication number
- NO20062398L NO20062398L NO20062398A NO20062398A NO20062398L NO 20062398 L NO20062398 L NO 20062398L NO 20062398 A NO20062398 A NO 20062398A NO 20062398 A NO20062398 A NO 20062398A NO 20062398 L NO20062398 L NO 20062398L
- Authority
- NO
- Norway
- Prior art keywords
- profiles
- dosage form
- controlled release
- daily oral
- oral controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Det er frembragt oksykodonformuleringer som produserer i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler. Toleransenivåer i samband med slike profiler og toleransenivåer i samband med bifasiske profiler er vist å ikke være statistisk ulike. De i det vesentlige flate, in vivo tilstandsstabile plasmaprofiler blir produsert av doseringsformer med i det vesentlige nulte ordens in vitro frigjøringsprofiler. Slike frigjøringsprofiler produserer for lav enkeltdose in vivo Cmaks-nivåer som kan redusere sannsynligheten for skadelige bivirkninger.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51588003P | 2003-10-29 | 2003-10-29 | |
PCT/US2004/036132 WO2005041968A2 (en) | 2003-10-29 | 2004-10-28 | Once-a-day, oral, controlled-release, oxycodone dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062398L true NO20062398L (no) | 2006-07-27 |
Family
ID=34549453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062398A NO20062398L (no) | 2003-10-29 | 2006-05-26 | Daglig, oral, kontrollert frigivnings oksycodon-doserings form |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1677798A2 (no) |
JP (1) | JP2007509979A (no) |
KR (1) | KR20060108690A (no) |
CN (1) | CN1933837A (no) |
AU (1) | AU2004285547A1 (no) |
BR (1) | BRPI0415639A (no) |
CA (1) | CA2546691A1 (no) |
EC (1) | ECSP066534A (no) |
IL (1) | IL175193A0 (no) |
MA (1) | MA28215A1 (no) |
NO (1) | NO20062398L (no) |
RU (1) | RU2006118323A (no) |
WO (1) | WO2005041968A2 (no) |
ZA (1) | ZA200604310B (no) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
ES2374717T3 (es) | 1999-10-29 | 2012-02-21 | Euro-Celtique S.A. | Formulaciones de hidrocodona de liberación controlada. |
JP2004512354A (ja) | 2000-10-30 | 2004-04-22 | ユーロ−セルティーク,エス.エイ. | ヒドロコドン放出制御製剤 |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
CA2723438C (en) | 2008-05-09 | 2016-10-11 | Gruenenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
WO2011009602A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Hot-melt extruded controlled release dosage form |
BR112012001244A2 (pt) | 2009-07-22 | 2020-12-08 | Gruünenthal Gmbh | Forma de dosagem resitente à adulteração, seu processo de produção, e embalagem contendo tal forma |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
AU2011236548A1 (en) * | 2010-04-07 | 2012-11-01 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
AR082862A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
MX2015016254A (es) | 2013-05-29 | 2016-04-20 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. |
MX371432B (es) | 2013-05-29 | 2020-01-30 | Gruenenthal Gmbh | Forma de dosificacion resistente al uso indebido que contiene una o mas particulas. |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
AU2015266117A1 (en) | 2014-05-26 | 2016-11-24 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
CN107889459A (zh) | 2015-04-24 | 2018-04-06 | 格吕伦塔尔有限公司 | 具有立即释放和对溶剂萃取的抗性的抗篡改剂型 |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
BR112019002007B1 (pt) | 2016-08-10 | 2024-01-16 | F. Hoffmann-La Roche Ag | Composição farmacêutica e uso de uma composição farmacêutica |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
RU2004134594A (ru) * | 2002-04-29 | 2005-06-27 | Алза Корпорейшн (Us) | Способы и лекарственные формы для контролируемой доставки оксикодона |
IL165361A0 (en) * | 2002-05-31 | 2006-01-15 | Alza Corp | Dosage forms and compositions for osmotic deliveryof variable dosages of oxycodone |
-
2004
- 2004-10-28 WO PCT/US2004/036132 patent/WO2005041968A2/en active Application Filing
- 2004-10-28 RU RU2006118323/15A patent/RU2006118323A/ru unknown
- 2004-10-28 BR BRPI0415639-0A patent/BRPI0415639A/pt not_active IP Right Cessation
- 2004-10-28 KR KR1020067010336A patent/KR20060108690A/ko not_active Application Discontinuation
- 2004-10-28 JP JP2006538357A patent/JP2007509979A/ja not_active Withdrawn
- 2004-10-28 AU AU2004285547A patent/AU2004285547A1/en not_active Abandoned
- 2004-10-28 CA CA002546691A patent/CA2546691A1/en not_active Abandoned
- 2004-10-28 EP EP04817492A patent/EP1677798A2/en not_active Withdrawn
- 2004-10-28 CN CNA2004800394188A patent/CN1933837A/zh active Pending
-
2006
- 2006-04-25 IL IL175193A patent/IL175193A0/en unknown
- 2006-04-28 EC EC2006006534A patent/ECSP066534A/es unknown
- 2006-04-28 MA MA28979A patent/MA28215A1/fr unknown
- 2006-05-26 NO NO20062398A patent/NO20062398L/no not_active Application Discontinuation
- 2006-05-26 ZA ZA200604310A patent/ZA200604310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP066534A (es) | 2006-11-24 |
AU2004285547A1 (en) | 2005-05-12 |
MA28215A1 (fr) | 2006-10-02 |
CN1933837A (zh) | 2007-03-21 |
BRPI0415639A (pt) | 2006-12-12 |
IL175193A0 (en) | 2008-04-13 |
CA2546691A1 (en) | 2005-05-12 |
JP2007509979A (ja) | 2007-04-19 |
WO2005041968A2 (en) | 2005-05-12 |
KR20060108690A (ko) | 2006-10-18 |
EP1677798A2 (en) | 2006-07-12 |
RU2006118323A (ru) | 2007-12-10 |
ZA200604310B (en) | 2007-11-28 |
WO2005041968A3 (en) | 2006-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
GEP20125701B (en) | Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile | |
MXPA05013142A (es) | Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer. | |
WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
CA2683786C (en) | Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects | |
SG166093A1 (en) | Inhibitors of brutonæs tyrosine kinase | |
MY147393A (en) | Administration of dipeptidyl peptidase inhibitors | |
TW200630093A (en) | Dose forms | |
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
MY143604A (en) | 2-amino-7,8-dihydro-6h-pyrido [4,3-d] pyrimidin-5-ones | |
TW200716628A (en) | Novel compounds | |
NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
NZ588913A (en) | Liver cancer drug | |
WO2004006859A3 (en) | Platinum compound | |
TNSN07263A1 (en) | Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | |
WO2008052139A3 (en) | Ultra low dose doxepin and methods of using the same to treat sleep disorders | |
CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
RU2007122391A (ru) | S-миртазапин для лечения приливов | |
EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
PL1718651T3 (pl) | Pochodne 7H-pirolopirymidyny | |
MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
TW200616951A (en) | Indole derivatives, their manufacture and use as pharmaceutial agents | |
UA93689C2 (ru) | Фармацевтическая композиция ингибиторов дипептидилпептидазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |